EyePoint Pharmaceuticals to Highlight DURAVYUTM (vorolanib intravitreal insert) Clinical and Regulatory Progress and Pipeline Innovation at R&D Day 2024 [Yahoo! Finance]
EyePoint Pharmaceuticals, Inc. (EYPT)
Last eyepoint pharmaceuticals, inc. earnings: 3/5 07:00 am
Check Earnings Report
Company Research
Source: Yahoo! Finance
– Positive twelve-month safety and efficacy data from Phase 2 DAVIO 2 clinical trial evaluating DURAVYU for the treatment of wet AMD reinforces potential as a sustained six-month maintenance therapy – – Phase 2 trial of DURAVYU in diabetic macular edema (DME) fully enrolled – – EyePoint to webcast its R&D Day event today at 8:00 a.m. ET – WATERTOWN, Mass., June 26, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced the Company will highlight clinical and regulatory developments for its lead pipeline program, DURAVYU ™ (vorolanib intravitreal insert), formerly known as EYP-1901, its Durasert E ™ sustained drug delivery technology, and early-stage programs during EyePoint's R&D Day today, Wednesday, June 26, 2024, from 8:00 a.m. to 9:30 a.m. ET. “EyePoint continues to pioneer the development of sustained-rel
Show less
Read more
Impact Snapshot
Event Time:
EYPT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EYPT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EYPT alerts
High impacting EyePoint Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
EYPT
News
- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $28.00 price target on the stock.MarketBeat
- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $30.00 price target on the stock.MarketBeat
- EyePoint Pharmaceuticals to Highlight DURAVYUTM (vorolanib intravitreal insert) Clinical and Regulatory Progress and Pipeline Innovation at R&D Day 2024GlobeNewswire
- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.MarketBeat
- EyePoint Pharmaceuticals to Host R&D Day on June 26, 2024 [Yahoo! Finance]Yahoo! Finance
EYPT
Earnings
- 5/8/24 - Miss
EYPT
Sec Filings
- 6/26/24 - Form 8-K
- 6/25/24 - Form 4
- 6/21/24 - Form 8-K
- EYPT's page on the SEC website